Half-Life of Methimazole
The elimination half-life of methimazole in euthyroid adults is approximately 5-6 hours, though this can be prolonged to 6-9 hours in hyperthyroid patients and shortened to 2-3 hours in some individuals.
Pharmacokinetic Details
The most rigorous pharmacokinetic study found that after intravenous administration of 10mg to healthy subjects, methimazole demonstrated an elimination half-life (t1/2 beta) of 4.9 to 5.7 hours 1. This study used highly sensitive gas chromatographic-mass spectrometric assay methods, providing reliable data.
Impact of Thyroid Status
The half-life varies based on thyroid function status:
- Euthyroid patients: 5-6 hours 1, 2
- Hyperthyroid patients: Prolonged to approximately 6-9 hours 3, 4
- Hypothyroid patients: Further prolonged to 13.6 hours 4
The mechanism appears to be altered hepatic microsomal drug metabolism—accelerated in hyperthyroidism and retarded in hypothyroidism 4.
Clinical Implications
Dosing Frequency
Despite the relatively short half-life, methimazole's pharmacokinetics allow for once-daily dosing 5. This is a key advantage over propylthiouracil (PTU), which requires three-times-daily dosing due to its even shorter 1-2 hour half-life 2. The drug concentrates in thyroid tissue and exerts effects on intrathyroidal iodine metabolism for periods exceeding measurable serum concentrations 2.
Special Populations
- Hepatic insufficiency: The elimination half-life is prolonged proportionally to the degree of hepatic impairment 1
- Renal insufficiency: No significant effect on elimination 1
- Interindividual variation: Generally small, though rare patients may show rapid elimination (half-life as short as 2.4-2.6 hours) 1
Absorption and Bioavailability
Methimazole is readily absorbed from the gastrointestinal tract with high absolute bioavailability of approximately 93% after oral administration 1. The drug is virtually non-protein-bound and has a volume of distribution of about 40L, approximating total body water 2, 3.